The FDA has told the makers of six flu vaccines that they need to add a notification to the label of their shots, warning of ...

GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an upfront ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

Noetik, an AI-native biotech company developing self-supervised machine learning and high-throughput spatial data to develop ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

GSK Pharma Q3 results 2025: GlaxoSmithKline Pharma Ltd announced its Q3 results today posting a solid jump in its net profit. Consolidated PAT for the quarter surged by a robust 402 per cent. At the ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British pharma ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.